Literature DB >> 24686546

FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition.

Jun Yu1, Wu Zhang, Feng Gao, Yuan-Xing Liu, Zhi-Yun Chen, Long-Yu Cheng, Shang-Fen Xie, Shu-Sen Zheng.   

Abstract

BACKGROUND: FBW7 is a tumor suppressor which regulates a network of proteins with central roles in cell division, cell growth and differentiation. This study aimed to evaluate the role of FBW7 in chemosensitivity and epithelial-mesenchymal transition (EMT) in different hepatocellular carcinoma (HCC) cell lines and to investigate the relevant underlying mechanisms.
METHODS: Different human HCC cell lines (Hep3B, Huh-7, and SNU-449) were cultured. The cell viability was evaluated by cell counting kit-8, and FBW7 mRNA transcription and protein expression were quantitated by real-time PCR and Western blotting. Expressions of vimentin (mesenchymal biomarker) and E-cadherin (epithelial biomarker) were evaluated by Western blotting and immunocytochemistry. Cell invasion was assayed by Transwell migration, and FBW7 plasmid or siRNA was used to evaluate the effect of FBW7 overexpression or silencing on cell chemosensitivity.
RESULTS: FBW7 expression affected tumor cell chemosensitivity to doxorubicin and tumor cell invasive capacity in different HCC cell lines. FBW7hi (high FBW7 expression) Hep3B and FBW7mi (median FBW7 expression) Huh-7 cells were more sensitive to doxorubicin and lower in invasive capacity than FBW7lo (low FBW7 expression) SNU-449 cells. Silencing of FBW7 in Huh-7 and Hep3B cells induced the resistance to doxorubicin and enhanced cell invasion, whereas overexpression of FBW7 in SNU-449 cells restored the sensitivity to doxorubicin and significantly reduced invasive capacity. Furthermore, doxorubicin induced EMT toward mesenchyme in HCC cells. Downregulation of FBW7 in Huh-7 and Hep3B cells or upregulation of FBW7 in SNU-449 cells altered the direction of EMT.
CONCLUSIONS: The level of FBW7 expression impacted the tumor resistance to doxorubicin and the invasion capability of HCC cells. FBW7 therefore may be a potential target for the chemotherapy of HCC through the regulation of EMT.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24686546     DOI: 10.1016/s1499-3872(14)60029-1

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  13 in total

1.  miR-223/FBW7 axis regulates doxorubicin sensitivity through epithelial mesenchymal transition in non-small cell lung cancer.

Authors:  Renyuan Li; Shengjun Wu; Xin Chen; Hongfei Xu; Peng Teng; Weidong Li
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.

Authors:  Takahiro Kodama; Justin Y Newberg; Michiko Kodama; Roberto Rangel; Kosuke Yoshihara; Jean C Tien; Pamela H Parsons; Hao Wu; Milton J Finegold; Neal G Copeland; Nancy A Jenkins
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

3.  14-3-3σ Gene Loss Leads to Activation of the Epithelial to Mesenchymal Transition Due to the Stabilization of c-Jun Protein.

Authors:  Kumarkrishna Raychaudhuri; Neelam Chaudhary; Mansa Gurjar; Roseline D'Souza; Jazeel Limzerwala; Subbareddy Maddika; Sorab N Dalal
Journal:  J Biol Chem       Date:  2016-06-03       Impact factor: 5.157

4.  FBXO9 Mediates the Cancer-Promoting Effects of ZNF143 by Degrading FBXW7 and Facilitates Drug Resistance in Hepatocellular Carcinoma.

Authors:  Zhenyu Wang; Xiaoxia Chen; Lianer Zhou; Xinge Zhao; Chao Ge; Fangyu Zhao; Haiyang Xie; Taoyang Chen; Hua Tian; Hong Li; Jinjun Li
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

5.  Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.

Authors:  Jia Ma; Fanpeng Zeng; Cong Ma; Haijie Pang; Binbin Fang; Chaoqun Lian; Bin Yin; Xueping Zhang; Zhiwei Wang; Jun Xia
Journal:  Am J Cancer Res       Date:  2016-06-01       Impact factor: 6.166

6.  Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis.

Authors:  Yufeng Wang; Zhikui Liu; Bowen Yao; Qing Li; Liang Wang; Cong Wang; Changwei Dou; Meng Xu; Qingguang Liu; Kangsheng Tu
Journal:  Mol Cancer       Date:  2017-07-17       Impact factor: 27.401

7.  Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy.

Authors:  Norihiro Ishii; Kenichiro Araki; Takehiko Yokobori; Akira Watanabe; Mariko Tsukagoshi; Norio Kubo; Hideki Suzuki; Fumiyoshi Saito; Bolag Altan; Yasuo Hosouchi; Ken Shirabe; Hiroyuki Kuwano
Journal:  Oncol Lett       Date:  2017-03-29       Impact factor: 2.967

Review 8.  Emerging role of F-box proteins in the regulation of epithelial-mesenchymal transition and stem cells in human cancers.

Authors:  Yizuo Song; Min Lin; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Stem Cell Res Ther       Date:  2019-04-18       Impact factor: 6.832

Review 9.  Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.

Authors:  Jun Cao; Ming-Hua Ge; Zhi-Qiang Ling
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

10.  Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1.

Authors:  Norihiro Ishii; Kenichiro Araki; Takehiko Yokobori; Dorgormaa Gantumur; Takahiro Yamanaka; Bolag Altan; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Yasuo Hosouchi; Hiroyuki Kuwano; Ken Shirabe
Journal:  Oncotarget       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.